Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential.
Adolescent
Autoantigens
/ immunology
Autoimmunity
Biomarkers
Cell Plasticity
/ immunology
Child
Child, Preschool
Cytokines
/ metabolism
Dendritic Cells
/ immunology
Diabetes Mellitus, Type 1
/ diagnosis
Disease Progression
Disease Susceptibility
Female
Gene Expression Profiling
Gene Expression Regulation
Humans
Immune Tolerance
Immunomodulation
Male
Phagocytosis
/ genetics
autoimmunity
dendritic cells
immune tolerance
phagocytosis
type 1 diabetes
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
08
2019
accepted:
15
11
2019
entrez:
19
12
2019
pubmed:
19
12
2019
medline:
11
11
2020
Statut:
epublish
Résumé
Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact, they contribute to maintaining tolerance to self-antigens, but they can also prompt an immunogenic response against them, leading to autoimmunity. Countless factors can potentially impact on the proper functionality of the DCs, which range from altered subset distribution, impaired phagocytic function to abnormal gene expression. Moreover, in T1D, metabolic dysregulation could impair DC functions as well. Indeed, since T1D clinical course is likely to be more aggressive in children and adolescents and entails severe dysglycemia, the aim of this study was to analyze circulating DCs subpopulations in pediatric T1D at different stages, as well as to characterize their phagocytosis ability and tolerance induction potential. Thus, pediatric patients newly diagnosed with T1D, with established disease and control subjects were recruited. Firstly, DCs subsets from peripheral blood were found quantitatively altered during the first year of disease, but recovered in the second year of progression. Secondly, to study the tolerogenic functionality of DCs, liposomes with phosphatidylserine (PS) were designed to mimic apoptotic beta cells, which are able to induce tolerance, as previously demonstrated by our group in DCs from adult patients with T1D. In this study, monocyte-derived DCs from pediatric patients with T1D and control subjects were assessed in terms of PS-liposomes capture kinetics, and transcriptional and phenotypic changes. DCs from pediatric patients with T1D were found to phagocyte PS-liposomes more slowly and less efficiently than DCs from control subjects, inversely correlating with disease evolution. Nonetheless, the transcription of PS receptors and immunoregulatory genes, cytokine profile, and membrane expression of immunological markers in DCs was consistent with tolerogenic potential after PS-liposomes phagocytosis. In conclusion, T1D progression in childhood entails altered peripheral blood DCs subsets, as well as impaired DCs phagocytosis, although tolerance induction could still function optimally. Therefore, this study provides useful data for patient follow-up and stratification in immunotherapy clinical trials.
Identifiants
pubmed: 31849983
doi: 10.3389/fimmu.2019.02811
pmc: PMC6892968
doi:
Substances chimiques
Autoantigens
0
Biomarkers
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2811Informations de copyright
Copyright © 2019 Rodriguez-Fernandez, Murillo, Villalba, Perna-Barrull, Cano-Sarabia, Gomez-Muñoz, Aguilera, Maspoch, Vazquez, Bel and Vives-Pi.
Références
Nanomedicine (Lond). 2017 Jun;12(11):1231-1242
pubmed: 28593827
FASEB J. 2004 Nov;18(14):1716-8
pubmed: 15345697
Acta Diabetol. 2019 Sep 30;:null
pubmed: 31570993
Front Immunol. 2019 Feb 06;10:148
pubmed: 30787930
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
Curr Opin Rheumatol. 2014 Sep;26(5):459-66
pubmed: 25036095
Diabetes. 2000 Aug;49(8):1325-33
pubmed: 10923633
Front Immunol. 2017 Oct 25;8:1356
pubmed: 29118755
PLoS One. 2015 Jun 03;10(6):e0127057
pubmed: 26039878
Mol Metab. 2017 Jul 08;6(9):943-957
pubmed: 28951820
J Clin Pathol. 1984 Jul;37(7):783-6
pubmed: 6747013
JAMA. 2016 Mar 15;315(11):1107-8
pubmed: 26978201
J Cell Biol. 2010 Jun 28;189(7):1059-70
pubmed: 20584912
Mediators Inflamm. 2015;2015:471719
pubmed: 26819498
Diabetes Care. 2012 Nov;35(11):2303-10
pubmed: 22787171
Annu Rev Cell Dev Biol. 2017 Oct 6;33:127-144
pubmed: 28613937
J Autoimmun. 2006 Mar;26(2):104-15
pubmed: 16431079
Front Immunol. 2014 Nov 10;5:566
pubmed: 25426118
N Engl J Med. 2017 Apr 13;376(15):1419-1429
pubmed: 28402773
Cytokine. 2018 Nov;111:194-205
pubmed: 30176557
Nature. 2016 Nov 24;539(7630):565-569
pubmed: 27828940
Front Immunol. 2017 Aug 02;8:909
pubmed: 28824635
Front Immunol. 2018 Feb 14;9:253
pubmed: 29491866
Diabetes. 2018 Aug;67(8):1481-1494
pubmed: 30030289
Virology. 2014 Nov;468-470:565-580
pubmed: 25277499
Diabetologia. 2019 Mar;62(3):408-417
pubmed: 30483858
Front Immunol. 2018 Jan 30;9:127
pubmed: 29441073
PLoS One. 2011;6(8):e23366
pubmed: 21876749
Diabetes. 2006 Sep;55(9):2588-94
pubmed: 16936208
Clin Immunol. 2007 Jun;123(3):281-8
pubmed: 17462956
Obes Sci Pract. 2017 Apr 26;3(2):127-133
pubmed: 28706730
Eur J Endocrinol. 2010 Mar;162(3):559-68
pubmed: 20022941
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Apoptosis. 2015 Mar;20(3):263-72
pubmed: 25604067
Front Immunol. 2019 Feb 22;10:181
pubmed: 30853957
FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):259-65
pubmed: 10575137
J Leukoc Biol. 2014 Aug;96(2):313-24
pubmed: 24782489
Cell Immunol. 1984 Feb;83(2):321-9
pubmed: 6692481
Immunity. 2011 Jul 22;35(1):82-96
pubmed: 21723156
Curr Top Microbiol Immunol. 2017;403:1-36
pubmed: 26305046
J Leukoc Biol. 2015 Apr;97(4):751-60
pubmed: 25624460
Diabetes. 2012 Jul;61(7):1661-3
pubmed: 22723273
Chest. 1993 Feb;103(2 Suppl):102S
pubmed: 8381344
Front Immunol. 2018 Jul 20;9:1645
pubmed: 30083153
Diabetes. 2014 Nov;63(11):3835-45
pubmed: 24939426